|
|
Bavarian Nordic AS - Comparative Business Analysis Snapshot
Business Description
Bavarian Nordic AS. The Group's principal activities are development and production of vaccines and immune therapy products. The Group applies gene therapy and new methodologies in vaccine delivery. The Group utilises three proprietary delivery technologies for its product development programmes: a pox virus vector, a retroviral vector and a cell encapsulation technology. The main product of the Group is the manufacture of smallpox vaccine. The ongoing clinical programmes involve HIV, malignant melanoma, smallpox and cancer research. The Group operates in Denmark, Germany, the US and Singapore.
Competitor Analysis
This analysis compares Bavarian Nordic AS with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
